J&J leans on Tremfya, cancer drugs to overcome Stelara losses
Source: BioPharma Dive - Latest News
A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street’s expectations and surpass $15 billion in first-quarter drug sales.